S

Sanofi

Global pharma company; vaccines and R&D

Training and Documentation Specialist

Full-TimePosted on 10/19/2026Deadline 12/31/26
No salary listed
Mid
Bachelor's
Singapore
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Bachelor's degree in Pharmacy, Science, Engineering, or a related Life Sciences or Technology field.
  • A minimum of 4 years of relevant experience in the pharmaceutical or biotechnology industry.
  • Ability to analyze complex data sets and identify patterns, discrepancies, and areas for improvement.
  • Strong verbal and written communication skills to train staff, report findings, collaborate with departments, and face audits and inspections.
  • Ability to work as part of an integrated, networked team and collaborate across functional, organizational, and location boundaries.
  • Strong analytical, consultative, and diagnostic skills, with the ability to make sound, data-based quality decisions.
  • Ability to work independently with little supervision and adapt to changing needs.
  • Ability to collaborate with cross-functional teams, including global partners, to meet project timelines.
  • Ability to present strategies to site management and other functions.
  • Familiarity with Digital 4.0 concepts and potential applications in Quality.
Responsibilities
  • Contribute to developing and implementing annual training programs to ensure compliance with Good Manufacturing Practices and company standards.
  • Identify training needs and develop customized training plans.
  • Support managers in establishing curricula for different areas.
  • Develop training materials with subject matter experts to address training needs and plans.
  • Conduct training sessions for new hires and existing employees on specific topics.
  • Evaluate training effectiveness through assessments, feedback, and performance metrics.
  • Support subject matter experts in updating training materials to reflect changes in regulations, procedures, and best practices.
  • Lead continuous improvement initiatives to enhance training materials and processes.
  • Support regulatory inspections and audits by presenting training records, processes, and materials.
  • Contribute to site Quality Management System training activities related to Deviation, CAPA, and Change Control.
  • Administer iLearn activities, including managing learning objects, groups, and assignments and running reports, to support Quality and HSE training needs within the assigned permissions.
  • Determine the best approach to operating the iLearn learning offer by applying approved Ways of Working.
  • Support the manager and training specialist in developing training plans in compliance with iLearn best practices.
  • Stay current with iLearn functionality changes by completing the corresponding training within defined timelines.
  • Coordinate with other decentralized administrators through regular meetings.
  • Update and manage the training catalog in iLearn.
  • Contribute iLearn expertise to site projects.
  • Create, modify, re-version, and inactivate learning objects, including online courses and on-the-job training, and create face-to-face or virtual training events and sessions according to approved processes, including testing in P2.
  • Request creation of non-Workday user profiles in accordance with iLearn user profile requirements, using the global interface for requests.
  • Manage iLearn groups, learning assignments, registrations, and completions, and run reports.
  • Liaise with the global iLearn Operations team on activities outside decentralized administrator permissions.
  • Comply with applicable iLearn Operations Global Quality documents and respond to iLearn Quality Control requests for data updates and corrections.
  • Contribute to deviation investigations or analysis related to the tool or its interface with other tools, as needed.
  • Support audits and inspections by demonstrating tool operation and providing inspection reports.
  • Provide level 2 support to learners.
  • Contribute to improvement of iLearn learner support, including knowledge-base enrichment.
  • Contribute to iLearn administration evolution projects, including process improvement and testing.
  • Provide backup or support for decentralized activities at other sites or entities, as needed.
  • Comply with the General Data Protection Regulation and data protection principles when handling personal data.
  • Manage the GxP documentation lifecycle, including document creation, revision, and obsolescence.
  • Collaborate with other departments to ensure document content addresses business needs and processes.
  • Ensure documentation content complies with regulatory requirements and company standards, with support from relevant experts.
  • Keep the overall documentation package lean by avoiding redundancies and duplication.
  • Ensure documentation is accurate, complete, and compliant with writing rules, including clarity and grammar.
  • Collect and prioritize documentation change needs and manage document updates.
  • Ensure documentation is regularly updated and aligned with current needs and processes.
  • Ensure document distribution and access comply with information classification levels.
  • Support internal and external audits and inspections by ensuring required documents are current and retrievable.
  • Represent the site in the global documentation Community of Practice and, if requested, participate in the Center of Excellence and ensure local communication.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...